Skip to content

The Application of the PDCA Management Model in Improving the Diagnostic Accuracy of AIG

The Application of the PDCA Management Model in Improving the Diagnostic Accuracy of AIG

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06557252
Enrollment
16
Registered
2024-08-16
Start date
2024-08-15
Completion date
2024-12-31
Last updated
2024-08-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Autoimmune Gastritis

Brief summary

Autoimmune gastritis is currently relatively rare in China due to its insidious onset, diverse clinical manifestations involving multiple systems such as digestive, hematological, and nervous systems, and its association with other autoimmune diseases. It can also be complicated by hyperplastic gastric polyps, gastric neuroendocrine tumors, gastric adenocarcinoma, and other diseases, making it prone to clinical misdiagnosis. As a form of gastritis in the post-Helicobacter pylori era, its detection rate has been gradually increasing with the continuous improvement of endoscopic technology in China. Applying the PDCA cycle management in disease diagnosis can significantly improve the detection rate of the disease, benefiting patients. Through the PDCA management model, this study further enhanced gastroenterologists' understanding of this disease from various aspects, aiming to improve the clinical diagnosis of autoimmune gastritis.

Interventions

BEHAVIORALPDCA training

Improve diagnostic rate

Sponsors

Ningbo No. 1 Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

Endoscopy center gastroenterologists in our hospital in 2024

Exclusion criteria

Doctors who withdrew from the PDCA management midway and stopped undergoing gastroscopy.

Design outcomes

Primary

MeasureTime frameDescription
Diagnostic Accuracy of AIG4monthsTo diagnose Autoimmune Gastritis (AIG), the following two criteria must be simultaneously met: Endoscopic or histopathological findings, or both, that are consistent with the characteristics of autoimmune gastritis. Positive gastric autoantibody status, including the presence of anti-parietal cell antibodies (PCA) or anti-intrinsic factor antibodies (IFA), or both.
The suspected diagnosis rate of AIG4monthsIf only the endoscopic or histopathological findings, or both, are consistent with the characteristics of autoimmune gastritis, but the gastric autoantibody status (anti-parietal cell antibodies or anti-intrinsic factor antibodies) is not confirmed to be positive, then the case should be considered as a suspected case of Autoimmune Gastritis (AIG).

Secondary

MeasureTime frameDescription
Parietal Cell Antibody(PCA)4monthsPCA is an important indicator in the diagnosis of AIG.
IF-Ab4monthsIFA is an important indicator in the diagnosis of AIG.

Countries

China

Contacts

Primary ContactLei Xu
xulei22@163.com+8613486659126

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026